Corbus Pharmaceuticals Holdings, Inc. 8-K

What Happened
Corbus Pharmaceuticals Holdings, Inc. announced on May 12, 2026 (via an 8-K filing) that it issued a press release disclosing financial information and operating metrics for its fiscal quarter ended March 31, 2026 and discussing its business outlook. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Filing date: May 12, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: fiscal quarter ended March 31, 2026.
• The company issued a press release (Exhibit 99.1) that discloses financial results, operating metrics and commentary on business outlook.
• The Form 8-K was signed by Chief Executive Officer Yuval Cohen.

Why It Matters
This filing provides the latest quarterly financial results and operating metrics directly from Corbus, plus management commentary on near-term expectations — information investors use to assess the company’s recent performance and outlook. The attached press release is the formal source for the specific figures and guidance; investors should review Exhibit 99.1 for the detailed numbers and any implications for revenue, cash position, or clinical program progress.